Indication intelligence, analysis and sector perception

Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.

AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.

The company was founded in 1999 and is headquartered in Alachua, Florida.

Company Website

 

Applied Genetic Technologies Corporation | (AGTC)

0  $0.00 (0.00%) Jul 27, 5:53pm

September 23, 2015
RegMed’s close: narrow ranges, low volume, fear and negative sentiment marginalize any bounce

September 17, 2015
RegMed’s close: headline, rates remain unchanged; “our” reality is the short side offers the strongest opportunity

September 17, 2015
Mixed open expected; RegMed, investors have a fundamental right to full disclosure from public companies; Applied Genetic Technologies (AGTC) has still not responded to investor and analyst inquiries

September 14, 2015
RegMed’s close: a slow melt up, risk continues to resonate as companies undervalue investor’s interests. Applied Genetic Technologies (AGTC) shares have migrated up and down as management awards themselves bonuses, no wonder sentiment alternates!

September 14, 2015
Higher open expected; RegMed – pick-up-sticks, the game of buying and selling “our” universe’s stocks as random up and downs always end up in a tangled pile.

September 11, 2015
RegMed’s close: the sector is caught in lack of investor orientation as to the foundation or share pricing and other scary factors. “Anticipation Is making me late and keeping me waiting” – Carly Simon.

September 11, 2015
Lower open expected; RegMed stocks are cheap and getting cheaper, even before the sector collapsed: the market has been considering “our” universe as damaged goods. The real issue is investors are growing jaded with cell therapy as it chugged along

September 10, 2015
RegMed’s close: lately it’s all about volatility’s direction – mostly uneven and always overdone. The middle road is where as traders buy after sell-offs and sell into strengths?

September 10, 2015
Higher open expected; the alternating daily closes don’t lie, the volatility of value destruction has been foreseeable

September 9, 2015
RegMed’s close: As the day progressed, anxiety mounted about holding onto positions as traders obliged with profit taking while market seasonality suggests a cautious outlook

35 companies, 1 interpreter!

Insight, foresight and recommendation

Roll Call

Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...

hold

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

  Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.

           

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.